GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...
Dr. Piotr Witkowski, director of the pancreatic and islet transplant program at the University of Chicago Transplant ...
Type 1 Diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic beta cells, leading to lifelong insulin dependency. While insulin therapy is central to T1D ...
Type 1 diabetes is thought to be caused by an autoimmune response that destroys the insulin-making cells in the pancreas, according to the U.S. Centers for Disease Control and Prevention. As a result, ...
When insulin-producing cells are damaged or destroyed and stop producing insulin, type 1 diabetes occurs. Insulin is needed to move blood sugar into cells throughout your body. An insulin ...
While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...
A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...
Stéphane Berneau does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...
Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes. Nature Metabolism , 2024; DOI: 10.1038/s42255-024-01139-z Cite This ...
Researchers in China say they've used stem cell therapy to reverse type 1 diabetes in a 25-year-old woman. She is the first person with type 1 diabetes to receive this kind of treatment for the ...
What Is Type 3 ... sure your diabetes medication is working well and adjust doses or timing if needed. Poorly controlled blood sugar can lead to many serious health issues. About 1 in 4 people ...
From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 ...